BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

BACKGROUND: Breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary treatment of numerous women. B-cell lymphoma 2 (BCL2), an antiapoptotic protein, has been proposed as a prognostic marker, but this effect is considered to relate to oes...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2010
נושאים:
Molecular Diagnostics
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938244/
https://ncbi.nlm.nih.gov/pubmed/20664598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605736
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים